<DOC>
	<DOCNO>NCT00887224</DOCNO>
	<brief_summary>The primary purpose study compare long-term efficacy safety desvenlafaxine succinate sustain release versus placebo adult Major Depressive Disorder , use randomize withdrawal design . Randomized withdrawal mean receive desvenlafaxine succinate sustain release predetermine period time , subject select chance either continue receive study drug withdrawn study drug receive placebo remainder participation trial . Subjects know group assign . The study consist 14-day screen period follow 8-week open-label period subject knowingly receive 50 mg/day desvenlafaxine succinate sustain release . Subjects respond treatment , demonstrate significant change depressive symptom , withdrawn participation end period . Responding subject receive additional 3 month open-label desvenlafaxine succinate sustain release dose . Subjects stable response treatment conclusion 3 month period randomize either desvenlafaxine succinate sustain release 50 mg/day placebo blind manner additional 6 month symptoms depression return . Following discontinuation point enrollment study , subject receive two week follow-up monitoring , include one week blind taper 25 mg/day desvenlafaxine succinate sustain release treatment subject take desvenlafaxine succinate sustain release prior discontinuation . Subjects assign placebo receive blind placebo taper . Following taper , subject evaluate one additional week monitor safety .</brief_summary>
	<brief_title>Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Adult , outpatient primary diagnosis Major Depressive Disorder ( depressive symptom least 30 day prior screen ) Hamilton Psychiatric Rating Scale Depression ( HAMD 17 ) total score &gt; = 20 Clinical Global Impressions ScaleSeverity ( CGIS ) score &gt; = 4 . Significant risk suicide assess clinician judgment , HAMD17 Columbia SuicideSeverity Rating Scale score . Past treatment desvenlafaxine succinate sustain release . Other eligibility criterion also apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Major Depressive Disorder</keyword>
</DOC>